B-CLL cells also responded to stimulation with loxoribine, Pam3CSK4, and MALP-2 (TLR7, TLR1/TLR2, and TLR2/TLR6 agonists, respectively). Here, TLR2 is linked to B-cell chronic lymphocytic leukemia.